FOLH1 and prostate carcinoma: Since its development in 2012 [21], the 68Ga-PSMA-11 injection kit has been widely used in PET/CT imaging of prostate cancer and evaluated in many clinical studies, and a vast amount of clinical data have been obtained worldwide in prospective studies, retrospective studies, the phase 3 VISION study, and investigator-initiated clinical trials [7, 8, 22–27].